| P2093 | author name string | Roger J Hajjar | |
| | Yoshiaki Kawase | |
| | Hung Ly | |
| | Ryuichi Yoneyama | |
| P2860 | cites work | Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a | Q22010899 |
| | Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics | Q28141424 |
| | Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease | Q28143064 |
| | LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 |
| | Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis | Q28213353 |
| | Cardiac adenoviral S100A1 gene delivery rescues failing myocardium | Q28296403 |
| | Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure | Q28354203 |
| | PKC-alpha regulates cardiac contractility and propensity toward heart failure | Q28589911 |
| | Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 |
| | S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles | Q29620465 |
| | Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results | Q31767833 |
| | Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium | Q31952673 |
| | beta-adrenergic receptor blockade in chronic heart failure | Q33831388 |
| | AAV vectors: is clinical success on the horizon? | Q33840994 |
| | Prospects for gene therapy for heart failure | Q33881236 |
| | In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction | Q33936885 |
| | Decreased efficiency of adenovirus-mediated gene transfer in aging cardiomyocytes | Q34074815 |
| | Adeno-associated virus vectors for gene therapy: more pros than cons? | Q34080580 |
| | Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade | Q34191737 |
| | Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure | Q34245088 |
| | Nonviral vectors in the new millennium: delivery barriers in gene transfer | Q34270234 |
| | Type 1 phosphatase, a negative regulator of cardiac function | Q34281889 |
| | Assessment of risks associated with cardiovascular gene therapy in human subjects | Q34353818 |
| | Myocardial gene therapy | Q34503413 |
| | Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis. | Q34542759 |
| | VEGF gene delivery for treatment of ischemic cardiovascular disease | Q34635640 |
| | Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. | Q35025591 |
| | Molecular enhancement of porcine cardiac chronotropy | Q35381580 |
| | Genetic, cellular and immune approaches to disease therapy: past and future | Q35647868 |
| | Modulation of ventricular function through gene transfer in vivo | Q36067860 |
| | Ultrarapid, highly efficient viral gene transfer to the heart | Q36144261 |
| | Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure | Q36304375 |
| | Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. | Q36441343 |
| | Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice | Q36735680 |
| | Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling | Q39752687 |
| | 'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. | Q40655750 |
| | A stable system for the high-titer production of multiply attenuated lentiviral vectors | Q40860697 |
| | Gene transfer by adeno-associated virus vectors into the central nervous system | Q41450710 |
| | In vivo gene transfer: a biological tool | Q41500672 |
| | High-efficiency, long-term cardiac expression of foreign genes in living mouse embryos and neonates. | Q41714490 |
| | Effects of adeno-associated virus DNA hairpin structure on recombination | Q42755152 |
| | Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain | Q44686125 |
| | Development of a novel fusogenic viral liposome system (HVJ-liposomes) and its applications to the treatment of acquired diseases | Q44811368 |
| | Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia | Q45060641 |
| | SERCA2A overexpression decreases the incidence of aftercontractions in adult rabbit ventricular myocytes | Q45142538 |
| | Enhancement of adenoviral gene transfer to adult rat cardiomyocytes in vivo by immobilization and ultrasound treatment of the heart. | Q45164875 |
| | Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart | Q45507049 |
| | Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo | Q45709105 |
| | Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity | Q45762593 |
| | In vivo gene transfection of human endothelial cell nitric oxide synthase in cardiomyocytes causes apoptosis-like cell death. Identification using Sendai virus-coated liposomes | Q45762805 |
| | Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. | Q45855123 |
| | Gene delivery to the myocardium by intrapericardial injection. | Q45862161 |
| | In vivo high-efficiency transcoronary gene delivery and Cre-LoxP gene switching in the adult mouse heart | Q45865309 |
| | Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins | Q45865601 |
| | Focal modification of electrical conduction in the heart by viral gene transfer | Q45872810 |
| | Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer | Q45887681 |
| | Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery | Q45888008 |
| | Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin | Q45889788 |
| | Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model | Q46213607 |
| | Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation. | Q51033467 |
| | Robust Adenoviral and Adeno-Associated Viral Gene Transfer to the In Vivo Murine Heart | Q58198543 |
| P921 | main subject | heart failure | Q181754 |
| | gene therapy | Q213901 |
| P304 | page(s) | 81-96 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | Physiology | Q1091804 |
| P1476 | title | Gene therapy in the treatment of heart failure | |
| P478 | volume | 22 | |